BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wong EKS, Kavanagh D. Diseases of complement dysregulation-an overview. Semin Immunopathol 2018;40:49-64. [PMID: 29327071 DOI: 10.1007/s00281-017-0663-8] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 11.3] [Reference Citation Analysis]
Number Citing Articles
1 Yoo SM, Chung SH. Targets of monoclonal antibodies for immunological diseases. Arch Pharm Res 2019;42:293-304. [PMID: 30426387 DOI: 10.1007/s12272-018-1087-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
2 Jayarangaiah A, Kariyanna PT, Chen X, Jayarangaiah A, Kumar A. COVID-19-Associated Coagulopathy: An Exacerbated Immunothrombosis Response. Clin Appl Thromb Hemost 2020;26:1076029620943293. [PMID: 32735131 DOI: 10.1177/1076029620943293] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 12.5] [Reference Citation Analysis]
3 de Boer ECW, van Mourik AG, Jongerius I. Therapeutic Lessons to be Learned From the Role of Complement Regulators as Double-Edged Sword in Health and Disease. Front Immunol 2020;11:578069. [PMID: 33362763 DOI: 10.3389/fimmu.2020.578069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Stach L, Dinley EKH, Tournier N, Bingham RP, Gormley DA, Bramhall JL, Taylor A, Clarkson JE, Welbeck KA, Harris CL, Feeney M, Hughes JP, Sepp A, Batuwangala TD, Kitchen SJ, Nichols EM. Novel Selection Approaches to Identify Antibodies Targeting Neoepitopes on the C5b6 Intermediate Complex to Inhibit Membrane Attack Complex Formation. Antibodies (Basel) 2021;10:39. [PMID: 34698051 DOI: 10.3390/antib10040039] [Reference Citation Analysis]
5 Agostinis C, Mangogna A, Balduit A, Aghamajidi A, Ricci G, Kishore U, Bulla R. COVID-19, Pre-Eclampsia, and Complement System. Front Immunol 2021;12:775168. [PMID: 34868042 DOI: 10.3389/fimmu.2021.775168] [Reference Citation Analysis]
6 de Jong S, Volokhina EB, de Breuk A, Nilsson SC, de Jong EK, van der Kar NCAJ, Bakker B, Hoyng CB, van den Heuvel LP, Blom AM, den Hollander AI. Effect of rare coding variants in the CFI gene on Factor I expression levels. Hum Mol Genet 2020;29:2313-24. [PMID: 32510551 DOI: 10.1093/hmg/ddaa114] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
7 Zhang L, Dai Y, Huang P, Saunders TL, Fox DA, Xu J, Lin F. Absence of complement component 3 does not prevent classical pathway-mediated hemolysis. Blood Adv 2019;3:1808-14. [PMID: 31196848 DOI: 10.1182/bloodadvances.2019031591] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Shin S, Seong Y, Lim BJ. Pathology of C3 Glomerulopathy. Child Kidney Dis 2019;23:93-9. [DOI: 10.3339/jkspn.2019.23.2.93] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Raina R, Sethi SK, Dragon-Durey MA, Khooblall A, Sharma D, Khandelwal P, Shapiro R, Boyer O, Yap HK, Bagga A, Licht C. Systematic review of atypical hemolytic uremic syndrome biomarkers. Pediatr Nephrol 2022. [PMID: 35118546 DOI: 10.1007/s00467-022-05451-2] [Reference Citation Analysis]
10 Schröder-Braunstein J, Kirschfink M. Complement deficiencies and dysregulation: Pathophysiological consequences, modern analysis, and clinical management. Mol Immunol 2019;114:299-311. [PMID: 31421540 DOI: 10.1016/j.molimm.2019.08.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
11 Santagostino A, Lombardi L, Dine G, Hirsch P, Misra SC. Paroxysmal Nocturnal Hemoglobinuria with a Distinct Molecular Signature Diagnosed Ten Years after Allogenic Bone Marrow Transplantation for Acute Myeloid Leukemia. Case Rep Hematol 2019;2019:8928623. [PMID: 30867971 DOI: 10.1155/2019/8928623] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Lin K, Zhang L, Kong M, Yang M, Chen Y, Poptic E, Hoffner M, Xu J, Tam C, Lin F. Development of an anti-human complement C6 monoclonal antibody that inhibits the assembly of membrane attack complexes. Blood Adv 2020;4:2049-57. [PMID: 32396613 DOI: 10.1182/bloodadvances.2020001690] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
13 Corvillo F, Okrój M, Nozal P, Melgosa M, Sánchez-Corral P, López-Trascasa M. Nephritic Factors: An Overview of Classification, Diagnostic Tools and Clinical Associations. Front Immunol 2019;10:886. [PMID: 31068950 DOI: 10.3389/fimmu.2019.00886] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
14 Kerr H, Herbert AP, Makou E, Abramczyk D, Malik TH, Lomax-Browne H, Yang Y, Pappworth IY, Denton H, Richards A, Marchbank KJ, Pickering MC, Barlow PN. Murine Factor H Co-Produced in Yeast With Protein Disulfide Isomerase Ameliorated C3 Dysregulation in Factor H-Deficient Mice. Front Immunol 2021;12:681098. [PMID: 34054871 DOI: 10.3389/fimmu.2021.681098] [Reference Citation Analysis]
15 Harris CL, Pouw RB, Kavanagh D, Sun R, Ricklin D. Developments in anti-complement therapy; from disease to clinical trial. Mol Immunol 2018;102:89-119. [PMID: 30121124 DOI: 10.1016/j.molimm.2018.06.008] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 10.3] [Reference Citation Analysis]
16 Frazer-Abel A, Kirschfink M, Prohászka Z. Expanding Horizons in Complement Analysis and Quality Control. Front Immunol 2021;12:697313. [PMID: 34434189 DOI: 10.3389/fimmu.2021.697313] [Reference Citation Analysis]
17 Urban A, Kowalska D, Stasiłojć G, Kuźniewska A, Skrobińska A, Arjona E, Alonso EC, Fenollosa Segarra MÁ, Jongerius I, Spaapen R, Satchell S, Thiel M, Ołdziej S, Rodriguez de Córdoba S, Okrój M. Gain-of-Function Mutations R249C and S250C in Complement C2 Protein Increase C3 Deposition in the Presence of C-Reactive Protein. Front Immunol 2021;12:724361. [PMID: 34899688 DOI: 10.3389/fimmu.2021.724361] [Reference Citation Analysis]
18 Mastrangelo A, Serafinelli J, Giani M, Montini G. Clinical and Pathophysiological Insights Into Immunological Mediated Glomerular Diseases in Childhood. Front Pediatr 2020;8:205. [PMID: 32478016 DOI: 10.3389/fped.2020.00205] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Barratt J, Weitz I. Complement Factor D as a Strategic Target for Regulating the Alternative Complement Pathway. Front Immunol 2021;12:712572. [PMID: 34566967 DOI: 10.3389/fimmu.2021.712572] [Reference Citation Analysis]
20 Fernandez-Ruiz R, Blank RB, Wu M, Belmont HM. C3 glomerulonephritis and systemic lupus erythematosus: A report of a patient treated with eculizumab and review of the literature. Lupus 2021;:9612033211027938. [PMID: 34192954 DOI: 10.1177/09612033211027938] [Reference Citation Analysis]
21 Schein TN, Blackburn TE, Heath SL, Barnum SR. Plasma levels of soluble membrane attack complex are elevated despite viral suppression in HIV patients with poor immune reconstitution. Clin Exp Immunol 2019;198:359-66. [PMID: 31461782 DOI: 10.1111/cei.13366] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Tzoumas N, Hallam D, Harris CL, Lako M, Kavanagh D, Steel DHW. Revisiting the role of factor H in age-related macular degeneration: Insights from complement-mediated renal disease and rare genetic variants. Surv Ophthalmol 2021;66:378-401. [PMID: 33157112 DOI: 10.1016/j.survophthal.2020.10.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
23 Vaterodt L, Holle J, Hüseman D, Müller D, Thumfart J. Short- and Long-Term Renal Outcome of Hemolytic-Uremic Syndrome in Childhood. Front Pediatr 2018;6:220. [PMID: 30131950 DOI: 10.3389/fped.2018.00220] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
24 Wong EKS, Hallam TM, Brocklebank V, Walsh PR, Smith-Jackson K, Shuttleworth VG, Cox TE, Anderson HE, Barlow PN, Marchbank KJ, Harris CL, Kavanagh D. Functional Characterization of Rare Genetic Variants in the N-Terminus of Complement Factor H in aHUS, C3G, and AMD. Front Immunol 2020;11:602284. [PMID: 33519811 DOI: 10.3389/fimmu.2020.602284] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Garred P, Tenner AJ, Mollnes TE. Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics. Pharmacol Rev 2021;73:792-827. [PMID: 33687995 DOI: 10.1124/pharmrev.120.000072] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
26 Song WC, FitzGerald GA. COVID-19, microangiopathy, hemostatic activation, and complement. J Clin Invest 2020;130:3950-3. [PMID: 32459663 DOI: 10.1172/JCI140183] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 12.0] [Reference Citation Analysis]
27 Heurich M, Föcking M, Mongan D, Cagney G, Cotter DR. Dysregulation of complement and coagulation pathways: emerging mechanisms in the development of psychosis. Mol Psychiatry 2021. [PMID: 34226666 DOI: 10.1038/s41380-021-01197-9] [Reference Citation Analysis]
28 Agostinis C, Balduit A, Mangogna A, Zito G, Romano F, Ricci G, Kishore U, Bulla R. Immunological Basis of the Endometriosis: The Complement System as a Potential Therapeutic Target. Front Immunol 2020;11:599117. [PMID: 33505394 DOI: 10.3389/fimmu.2020.599117] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
29 Geller A, Yan J. The Role of Membrane Bound Complement Regulatory Proteins in Tumor Development and Cancer Immunotherapy. Front Immunol 2019;10:1074. [PMID: 31164885 DOI: 10.3389/fimmu.2019.01074] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 10.3] [Reference Citation Analysis]
30 Ahmad SB, Bomback AS. C3 Glomerulopathy: Pathogenesis and Treatment. Adv Chronic Kidney Dis 2020;27:104-10. [PMID: 32553242 DOI: 10.1053/j.ackd.2019.12.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
31 Shears A, Steele C, Craig J, Jolles S, Savic S, Hague R, Coulter T, Herriot R, Arkwright PD. Clinical Outcome and Underlying Genetic Cause of Functional Terminal Complement Pathway Deficiencies in a Multicenter UK Cohort. J Clin Immunol 2022. [PMID: 35084692 DOI: 10.1007/s10875-022-01213-9] [Reference Citation Analysis]
32 Kamala O, Malik TH, Hallam TM, Cox TE, Yang Y, Vyas F, Luli S, Connelly C, Gibson B, Smith-Jackson K, Denton H, Pappworth IY, Huang L, Kavanagh D, Pickering MC, Marchbank KJ. Homodimeric Minimal Factor H: In Vivo Tracking and Extended Dosing Studies in Factor H Deficient Mice. Front Immunol 2021;12:752916. [PMID: 34956184 DOI: 10.3389/fimmu.2021.752916] [Reference Citation Analysis]
33 Zipfel PF, Wiech T, Stea ED, Skerka C. CFHR Gene Variations Provide Insights in the Pathogenesis of the Kidney Diseases Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy. J Am Soc Nephrol 2020;31:241-56. [PMID: 31980588 DOI: 10.1681/ASN.2019050515] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
34 Gholizad-Kolveiri S, Hooman N, Alizadeh R, Hoseini R, Otukesh H, Talebi S, Akouchekian M. Whole exome sequencing revealed a novel homozygous variant in the DGKE catalytic domain: a case report of familial hemolytic uremic syndrome. BMC Med Genet 2020;21:169. [PMID: 32838746 DOI: 10.1186/s12881-020-01097-9] [Reference Citation Analysis]
35 Carlisi M, Mancuso S, Caimi G, Siragusa S. Thrombotic risk in paroxysmal nocturnal hemoglobinuria-like (PNH-like) phenotype. Clin Hemorheol Microcirc 2021;79:491-503. [PMID: 32116238 DOI: 10.3233/CH-190735] [Reference Citation Analysis]
36 Ort M, Dingemanse J, van den Anker J, Kaufmann P. Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway. Front Immunol 2020;11:599417. [PMID: 33362783 DOI: 10.3389/fimmu.2020.599417] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Berger N, Alayi TD, Resuello RRG, Tuplano JV, Reis ES, Lambris JD. New Analogs of the Complement C3 Inhibitor Compstatin with Increased Solubility and Improved Pharmacokinetic Profile. J Med Chem 2018;61:6153-62. [PMID: 29920096 DOI: 10.1021/acs.jmedchem.8b00560] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
38 van Beers JJBC, Damoiseaux JGMC. Treatment of Autoimmune Diseases with Therapeutic Antibodies: Lessons Learned from PID Patients Allow for Stratification of the Infection Risk. Methods Mol Biol 2022;2313:27-44. [PMID: 34478130 DOI: 10.1007/978-1-0716-1450-1_2] [Reference Citation Analysis]
39 Morgan BP, Kavanagh D. Introduction to complement in health and disease: novel aspects and insights. Semin Immunopathol 2018;40:1-2. [DOI: 10.1007/s00281-017-0664-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
40 Smith-Jackson K, Yang Y, Denton H, Pappworth IY, Cooke K, Barlow PN, Atkinson JP, Liszewski MK, Pickering MC, Kavanagh D, Cook HT, Marchbank KJ. Hyperfunctional complement C3 promotes C5-dependent atypical hemolytic uremic syndrome in mice. J Clin Invest 2019;129:1061-75. [PMID: 30714990 DOI: 10.1172/JCI99296] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
41 Bongetti E, Kavanagh D, Martin K, Bendall A, Hill P, Steinberg A, Rajaram Y, Ierino F. Cocaine-associated atypical haemolytic uraemic syndrome in a genetically susceptible individual. Nephrology (Carlton) 2020;25:518-21. [PMID: 31900968 DOI: 10.1111/nep.13690] [Reference Citation Analysis]
42 Knoop M, Haller H, Menne J. [Human genetics in atypical hemolytic uremic syndrome-its role in diagnosis and treatment]. Internist (Berl) 2018;59:799-804. [PMID: 29995248 DOI: 10.1007/s00108-018-0455-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
43 Corvillo F, Akinci B. An overview of lipodystrophy and the role of the complement system. Mol Immunol 2019;112:223-32. [PMID: 31177059 DOI: 10.1016/j.molimm.2019.05.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
44 Umnyakova ES, Gorbunov NP, Zhakhov AV, Krenev IA, Ovchinnikova TV, Kokryakov VN, Berlov MN. Modulation of Human Complement System by Antimicrobial Peptide Arenicin-1 from Arenicola marina. Mar Drugs 2018;16:E480. [PMID: 30513754 DOI: 10.3390/md16120480] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
45 Willems E, Lorés-Motta L, Zanichelli A, Suffritti C, van der Flier M, van der Molen RG, Langereis JD, van Drongelen J, van den Heuvel LP, Volokhina E, van de Kar NC, Keizer-Garritsen J, Levin M, Herberg JA, Martinon-Torres F, Wessels HJ, de Breuk A, Fauser S, Hoyng CB, den Hollander AI, de Groot R, van Gool AJ, Gloerich J, de Jonge MI. Quantitative multiplex profiling of the complement system to diagnose complement-mediated diseases. Clin Transl Immunology 2020;9:e1225. [PMID: 33318796 DOI: 10.1002/cti2.1225] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]